AZD1305
As of the edition of 20 October 2026, AZD1305 is a small molecule: went quiet in 2009; acts on CACNA1C, CACNA1D and CACNA1F and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2009
- Kind
- Small molecule
- Registered trials
- 13, 1 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B and 1 company-target row on route A because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of AZD1305.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company-target row is on route A because of AZD1305.
See the 1 company-target row on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| CACNA1F | Voltage-dependent L-type calcium channel subunit alpha-1F | O60840 |
| CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Q01668 |
| KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Q12809 |
| CACNA1S | Voltage-dependent L-type calcium channel subunit alpha-1S | Q13698 |
| CACNA1C | Voltage-dependent L-type calcium channel subunit alpha-1C | Q13936 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 8 | 0 | 1 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 13 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2007 to now |